If you need to inquire about Bayer product, please contact us through the following telephone:

Hotline: 400-810-0360 (available by mobile or telephone)

We will try our best to provide you the information about Bayer products, but we can't propose any specific diagnosis and treatment suggestions for patients' conditions. If you have any discomfort after medication, please go to see your doctor and receive timely medical treatment.

If you want to report a side effect or quality complaint, please contact your health care professional (e.g. treating physician or pharmacist) or your local health authority, Inquiries can also be directed to:

If you observe adverse event after Bayer Animal Health product application, you can transfer the information to us directly by:

Bayer China
Pharmaceuticals Division
The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing and Guangzhou.
Bayer constructed a pharmaceutical production and packaging facility in Beijing from 1995 to 1997, manufacturing solid and semisolid products. To meet the growing needs of the Chinese market, the company invested significantly in the extension of the company’s Beijing site. The site increased its production capacity several times following the extension and was equipped with state-of-the-art technology. In 2011, the Beijing site received the “Good Manufacturing Practice” certification from the Beijing Drug Administration Bureau.
In anticipation of increasing product demand in China, Bayer invested EUR 100 million to significantly increase the production capacity of its Beijing plant. The capacity extension is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The extension includes improved logistics for fully automated material handling, analytical laboratories, and high-speed packaging lines.
At the same time, Bayer is forming long-term strategic alliances with well-known academic institutes worldwide to drive fundamental research and explore the frontiers of drug discovery. In China, Bayer is strengthening the partnerships and strategic alliances with leading Chinese academic institutes such as Tsinghua University, Peking University and the Shanghai Institute of Organic Chemistry, to accelerate the translation of fundamental research into clinical treatment and improve China’s pharmaceutical innovation and R&D capabilities. In March 2018, Bayer celebrated its ten years of partnership with Tsinghua University and the two sides extended their strategic partnership to extend the innovative drug discovery alliance for another three years.
Bayer was one of the earliest companies to focus on county-level medical service capabilities in China and continues to invest in this area. Over the past ten years, over 45,000 physicians and hospital executives across 26 provinces have been trained under the “Go West” project. In 2018, the “Go West” project officially entered the third five-year period. In the next five years, the project will be extended to 31 provinces, cities, and regions around the country to increase the coverage outside the central and western regions.
The Pharmaceuticals Division’s Radiology business is a world-renowneddiagnostic imaging solutions provider. In the field of Radiology, Bayer provides solution with imaging contrast media, injection devices and informatics in China. Bayer is seen as the leading expert bringing Chinese radiologists and society to the best science through robust education programs. Supported by the legacy Ultravist in CT modality and Madred injectors, Bayer is also seen as the innovation leader in MR portfolio by Gadovist with whole body indication and liver specific Primovist.
Consumer Health Division
Bayer’s Consumer Health Division is a leader in the global consumer health marketplace. It operates in more than 100 countries and maintains several manufacturing and research-and-development (R&D) sites.
The division’s rich history of innovation began in 1899 with the introduction of Bayer’s flagship global consumer brand, Bayer Aspirin?. In 2005, Bayer acquired Roche’s OTC business and in October 2014 Bayer completed the acquisition of Merck’s global Consumer Care business.
Today, the Consumer Health divison offers to consumers some of the world’s best-known and most trusted over-the-counter medications,nutritional supplements and other self-care products. The portfolio includes strong brands in selected categories in which the company competes, including Allergy, Analgesics, Cardiovascular Risk Prevention, Cough & Cold, Dermatology, Gastrointestinals, Dietary Supplements.
Crop Science Division
Bayer’s Crop Science division is aligned with the long-term trends of the agricultural markets. The aim is to help shape the future of the agricultural industry with innovative solutions that enable the production of sufficient high-quality food, animal feed and renewable raw materials for a growing world population despite the limited amount of available arable land.
We want to contribute to global food security through an environmentally friendly and sustainable increase in agricultural productivity. Our strength in innovation is intended to benefit both our customers and society as a whole and be the source of our long-term growth.
Bayer has been active for over 60 years in Chinese agriculture, marked with constant efforts to introduce new technologies to Chinese farmers, ranging from the launches of products in recent years covering a large range of crops, namely rice, corn, wheat, vegetables and fruits, to services provided to farmers on crop protection solutions, safe use of agrichemicals and application technologies. As a global player, Bayer’s production site in Hangzhou is not only supplying products for domestic use, but also manufacturing for farmers in the rest of Asia as well as North and Latin America.
The Crop Science Division has also been in cooperation with authorities such as the Ministry of Agriculture, The National Agro-Tech Extension and Service Center, organizations such as the Chinese Academy of Agricultural Sciences, as well as joint efforts with public partners to develop sustainable agriculture in China.
Through the latest technology and decision science, we make the company's operation and agriculture to a higher level and realize the digital transformation. We accelerate our and our partners' research with more advanced solutions, digital tools and data analysis. We use cutting-edge technology to help growers integrate data so as to ensure more efficient use of resources and tap the potential in agricultural. We help growers practice sustainable agricultural and manage the farmland sufficiently by making use of the data at hand. We customize solutions to the needs of growers. We persist in innovation so that we can make crop management more environment friendly, with higher economic benefits and higher quality.
Bayer’s business unit Animal Health offers a number of products for farm and companion animals. Bayer is one of the leading suppliers of veterinary products in China with its head office and a Good Manufacturing Practice certified plant in Chengdu, Sichuan province.
Follow Us
Last updated:2020-06-01
XML 地图 | Sitemap 地图
Bayer China -Divisions


Seite verkleinern Normalansicht Seite vergr??ern


Bayer HealthCare – a strong player on the Chinese health care market
Bayer’s health care business in China goes back to 1936, when the company began producing Aspirin in Shanghai. In November 1997, what was then known as the Pharmaceuticals Business Group started the production of pharmaceuticals in Beijing. Today, a wide range of products are manufactured and Bayer is among China’s largest and fastest-growing health care companies.

Bayer HealthCare China is made up of three divisions: Pharmaceuticals, Consumer Care and Animal Health. Represented in more than 70 cities, Bayer HealthCare Pharmaceuticals offers a product line covering general medicine, women’s health, neurology, cardiology, hematology, men’s health and diagnostic imaging. In June 2011, the headquarters of the global primary care business was relocated to Beijing.

Bayer operates a modern production facility for a number of pharmaceutical products in Beijing and a site in Guangzhou. An expansion program quadrupled production capacity in 2008. In the same year, Bayer HealthCare acquired the over-the-counter (OTC) cough and cold portfolio of the Chinese company Topsun Science and Technology QidongGaitianli Pharmaceutical. This acquisition greatly strengthened Bayer’s presence in China, which is also one of the world’s fastest-growing OTC markets.

In the field of animal health, BHC offers a number of veterinary products, feed additives and aquaculture products, which it manufactures in Chengdu.

In early 2009, Bayer established a global research and development center in Beijing, the company's fourth such center worldwide. The center focuses on phase I to phase III trials in China and the Asia/Pacific region. These trials form an integral part of Bayer HealthCare’s global development programs. Around 120 employees concentrate on substances in the current pharmaceutical pipeline and on in-licensed assets which are designated for the Asian markets.

In addition, Bayer HealthCare also actively works with external partners including research and academic institutions such as the Shanghai Institute of Organic Chemistry (SIOC), Tsinghua University – with which Bayer is cooperating to discover new disease-related targets in the core areas of Bayer’s pharmaceutical research –, or the 301 Hospital in Beijing in the area of women’s health care. Bayer also cooperates with the National Pharmaceutical Engineering Research Center (NPERC) in Shanghai in a Ph.D. research program in the area of biodegradable polymers using the technology platform developed at NPERC.

Crop protection products from Hangzhou for Asia and America

To achieve sustainable economic and social progress, China needs to ensure reliable food supplies for its more than 1.3 billion citizens. This is where Bayer CropScience has an important role to play. Bayer CropScience China Co. Ltd operates a modern production site – China's first agrochemical joint venture – in Hangzhou, manufacturing a variety of crop protection products for China, Asia and North and Latin America. Bayer CropScience has launched 40 products in China over the past 10 years.

The company endeavors to expand its market position through customer loyalty programs specially developed for China. The “Food Chain Partnership” program targets all partners in the agricultural sector who are involved in the supply of food, working together with them to strengthen the integrated value chain. Partners include international companies such as Wal-Mart and Metro. In addition, Bayer runs a number of educational programs, including the AgriCare project and various cooperative programs with the Chinese Ministry of Agriculture. These projects also train Chinese farmers in modern crop management and growing methods.

Good long-term growth prospects for Bayer MaterialScience

Bayer’s business in China began in 1882 with the sale of textile dyes and specialty chemicals for use in industrial processes. Today, Bayer MaterialScience – the subgroup with the strongest presence in the Chinese market – produces polyurethane raw materials, polycarbonates, and raw materials for coatings, adhesives and specialties. Principal customers are the automotive, electrical/electronics, construction and sports and leisure industries. Bayer’s products and solutions are used in countless applications. Bayer MaterialScience expects to continue its good growth in China in the medium and long term and is therefore expanding its capacities there, including its local customer service.

Bayer MaterialSciencehas announced plans to invest EUR 110 million in the establishment of new customer centers in China by 2012 to serve the country’s rapidly expanding manufacturing sector from a local base. The facilities comprise polyurethanes systems houses, a new polycarbonate sheet facility and a Color Competence and Design Center for polycarbonates. Thenew centers will therefore be strategically located close to major customers in Shanghai, Qingdao, Chongqing and Guangzhou.

Construction of the systems house in Qingdao began in May 2011. Polyurethanes systems houses ensure prompt and flexible delivery to customers and support them in formulating products for special applications. The building complex will be the first EcoCommercial Building built under the Bayer EcoCommercial Building Program in China. The aim of this program is to develop sustainable construction industry solutions in China together with Chinese partners.

Bayer MaterialScience is also carrying out extensive research and development work in China,and plans to expand its Polymer Research and Development Center in Shanghai. Research activities will concentrate on areas in which China plays a leading global role, such as wind turbines and solar energy plants.

Bayer Integrated Site Shanghai (BISS)

At the Bayer Integrated Site in the Shanghai Chemical Industry Park, Bayer MaterialScience operates world-scale production facilities for plastics and for raw materials used in the manufacture of foams and coatings. The total investment planned for this site through 2012 amounts to EUR 2.1 billion.

The facilities include a production plant for the polycarbonate Makrolon? with a capacity of 200,000 metric tons per year and a production facility for diphenylmethanediisocyanate (MDI) with a capacity of 350,000 tons. There are also plants for the production of the coating raw material hexamethylenediisocyanate (HDI) with an annual capacity of 30,000 tons and facilities for polyurethane dispersions (PUD) with a total capacity of 20,000 tons. In addition, a 250,000-tons-per-year toluene diisocyanate (TDI) plant is being officially inaugurated in November 2011.

Further investment of some EUR 1 billion isto take placein the coming years. Capacities for both MDI and polycarbonate are to be more than doubled, to 1 million tons and 500,000 tons per year respectively. The construction of a 50,000-tons-per-year production facility for the coating raw material HDI is also planned to add to the existing capacity.

Including these capacity expansions, the total investment at the Bayer Integrated Site Shanghai amounts to more than EUR 3 billion.

The facilities set standards for energy-efficient and environmentally responsible production. The TDI facility, for example, features the modern gas phase process. This enables energy savings of up to 60 percent compared with a conventional plant of the same size. The new process technology uses up to 80 percent less solvent, and cuts investment costs for this type of large-scale facility by about 20 percent. The existing and future HDI plants also make use of an innovative gas phase technology.

Not only is Bayer represented in China with all of its subgroups, the company has also committed significant internal resources to its projects here. The service company Bayer Technology Services helps to ensure that Bayer meets international technological and environmental standards at all sites. Together with Bayer MaterialScience,Bayer Technology Services develops process-integrated technologies designed to conserve energy, recycle materials and minimize environmental impact.

  • Share to:
Follow Us
XML 地图 | Sitemap 地图